MCID: HYP064
MIFTS: 40

Hypogonadotropism

Categories: Endocrine diseases

Aliases & Classifications for Hypogonadotropism

MalaCards integrated aliases for Hypogonadotropism:

Name: Hypogonadotropism 12 54 15
Hypogonadism 71

Classifications:



External Ids:

Disease Ontology 12 DOID:7455
UMLS 71 C0020619

Summaries for Hypogonadotropism

MalaCards based summary : Hypogonadotropism, also known as hypogonadism, is related to congenital hypogonadotropic hypogonadism and hypogonadotropic hypogonadism 7 with or without anosmia. An important gene associated with Hypogonadotropism is RNF216 (Ring Finger Protein 216), and among its related pathways/superpathways are Peptide ligand-binding receptors and GnRH secretion. The drugs Liraglutide and Dihydrotachysterol have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and prostate, and related phenotypes are endocrine/exocrine gland and reproductive system

Related Diseases for Hypogonadotropism

Diseases related to Hypogonadotropism via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 370, show less)
# Related Disease Score Top Affiliating Genes
1 congenital hypogonadotropic hypogonadism 33.2 GNRHR ANOS1
2 hypogonadotropic hypogonadism 7 with or without anosmia 33.0 PROKR2 GNRHR GNRH1 ANOS1
3 hypogonadotropic hypogonadism 23 without anosmia 32.8 PROKR2 GNRHR GNRH1 ANOS1
4 amenorrhea 31.0 PRL GNRHR GNRH1
5 hypogonadotropic hypogonadism 30.8 TACR3 TAC3 PROKR2 PRL KISS1R KISS1
6 sexual disorder 30.7 PRL GNRH1
7 hypopituitarism 30.6 PROKR2 PRL GNRH1
8 normosmic congenital hypogonadotropic hypogonadism 30.6 TACR3 TAC3 PROKR2 KISS1R KISS1 GNRHR
9 empty sella syndrome 30.6 PRL GNRH1
10 pituitary hormone deficiency, combined, 2 30.6 PRL GNRH1
11 precocious puberty 30.4 KISS1R KISS1 GNRH1
12 hypothalamic disease 30.4 PRL GNRH1
13 anovulation 30.2 PRL KISS1 GNRH1
14 congenital hypopituitarism 30.1 PROKR2 PRL
15 oligospermia 30.1 PRL GNRHR
16 pituitary stalk interruption syndrome 30.1 PROKR2 PRL
17 estrogen excess 30.1 PRL GNRH1
18 ovarian disease 30.0 PRL KISS1 GNRH1
19 premature ovarian failure 1 29.9 PRL KISS1R KISS1 GNRH1
20 central precocious puberty 29.8 KISS1R KISS1 GNRH1
21 kallmann syndrome 29.8 TACR3 TAC3 RNF216 PROKR2 PRL OTUD4
22 charge syndrome 29.7 TACR3 TAC3 PROKR2 KISS1R GNRHR GNRH1
23 renal hypodysplasia/aplasia 1 29.6 PROKR2 GNRH1 ANOS1
24 coloboma of macula 28.8 TACR3 PROKR2 KISS1R GNRHR ANOS1
25 choanal atresia, posterior 28.8 TACR3 PROKR2 GNRHR ANOS1
26 hypogonadism 28.5 TACR3 TAC3 RNF216 PROKR2 PRL KISS1R
27 septooptic dysplasia 28.2 PROKR2 PRL GNRHR GNRH1 ANOS1
28 cryptorchidism, unilateral or bilateral 27.9 TACR3 TAC3 PROKR2 PRL KISS1R KISS1
29 hypogonadotropic hypogonadism 12 with or without anosmia 12.7
30 hypogonadotropic hypogonadism 1 with or without anosmia 12.7
31 hypogonadotropic hypogonadism 21 with or without anosmia 12.7
32 hypogonadotropic hypogonadism 10 with or without anosmia 12.7
33 hypogonadotropic hypogonadism 8 with or without anosmia 12.7
34 hypogonadotropic hypogonadism 14 with or without anosmia 12.7
35 hypogonadotropic hypogonadism 20 with or without anosmia 12.7
36 hypogonadotropic hypogonadism 11 with or without anosmia 12.7
37 hypogonadotropic hypogonadism 13 with or without anosmia 12.7
38 hypogonadotropic hypogonadism 15 with or without anosmia 12.7
39 hypogonadotropic hypogonadism 16 with or without anosmia 12.7
40 hypogonadotropic hypogonadism 9 with or without anosmia 12.7
41 hypogonadotropic hypogonadism 4 with or without anosmia 12.7
42 hypogonadotropic hypogonadism 5 with or without anosmia 12.7
43 hypogonadotropic hypogonadism 17 with or without anosmia 12.7
44 hypogonadotropic hypogonadism 19 with or without anosmia 12.7
45 hypogonadotropic hypogonadism 22 with or without anosmia 12.7
46 hypogonadotropic hypogonadism 18 with or without anosmia 12.6
47 hypogonadotropic hypogonadism 3 with or without anosmia 12.6
48 hypogonadotropic hypogonadism 2 with or without anosmia 12.6
49 hypogonadotropic hypogonadism 6 with or without anosmia 12.6
50 leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism 12.6
51 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 12.6
52 hypogonadotropic hypogonadism 24 without anosmia 12.4
53 multicore myopathy with mental retardation, short stature, and hypogonadotropic hypogonadism 12.3
54 boucher-neuhauser syndrome 12.3
55 gordon holmes syndrome 12.2
56 isolated congenital hypogonadotropic hypogonadism 12.2
57 adrenal hypoplasia, congenital 12.2
58 polr3-related leukodystrophy 12.2
59 bosma arhinia microphthalmia syndrome 12.1
60 hypogonadotropic hypogonadism-severe microcephaly-sensorineural hearing loss-dysmorphism syndrome 12.1
61 rare female infertility due to a congenital hypogonadotropic hypogonadism 12.1
62 rare disorder with hypogonadotropic hypogonadism 12.0
63 hypogonadotropic hypogonadism associated with other endocrinopathies 12.0
64 hypogonadotropic hypogonadism-frontoparietal alopecia syndrome 12.0
65 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 12.0
66 moebius syndrome-axonal neuropathy-hypogonadotropic hypogonadism syndrome 12.0
67 isolated gonadotropin-releasing hormone deficiency 11.8
68 leptin deficiency or dysfunction 11.7
69 hemochromatosis, type 1 11.6
70 prader-willi syndrome 11.4
71 hartsfield syndrome 11.4
72 hemochromatosis type 2 11.4
73 johnson neuroectodermal syndrome 11.4
74 waardenburg syndrome, type 2e 11.3
75 leptin receptor deficiency 11.3
76 martsolf syndrome 11.2
77 oliver-mcfarlane syndrome 11.2
78 kallmann syndrome with spastic paraplegia 11.2
79 congenital disorder of glycosylation, type it 11.2
80 leukodystrophy, hypomyelinating, 11 11.2
81 rab18 deficiency 11.2
82 slti salem syndrome 11.1
83 aromatase excess syndrome 11.0
84 poikiloderma with neutropenia 11.0
85 hemochromatosis, type 3 11.0
86 hemochromatosis, type 4 11.0
87 alopecia, neurologic defects, and endocrinopathy syndrome 11.0
88 aromatase deficiency 11.0
89 intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 11.0
90 hemochromatosis, type 5 11.0
91 culler-jones syndrome 11.0
92 polyendocrine-polyneuropathy syndrome 11.0
93 infertility 10.6
94 ataxia and polyneuropathy, adult-onset 10.5
95 azoospermia 10.5
96 impotence 10.4
97 hypoadrenocorticism, familial 10.4
98 infant gynecomastia 10.4
99 gynecomastia 10.4
100 aceruloplasminemia 10.4
101 pituitary gland disease 10.4
102 male infertility 10.3
103 pituitary infarct 10.3 PRL GNRH1
104 polyp of corpus uteri 10.3 PRL GNRH1
105 rete ovarii adenoma 10.3 PRL GNRH1
106 rete ovarii neoplasm 10.3 PRL GNRH1
107 salpingitis isthmica nodosa 10.3 PRL GNRH1
108 luteoma 10.3 PRL GNRH1
109 pituitary-dependent cushing's disease 10.3 PRL GNRH1
110 ovarian benign neoplasm 10.3 PRL GNRH1
111 mixed cerebral palsy 10.3 PRL GNRH1
112 thalassemia 10.3
113 growth hormone secreting pituitary adenoma 10.3 PRL KISS1
114 pituitary apoplexy 10.3 PRL GNRH1
115 hyperprolactinemia 10.3
116 hypoglycemia 10.3
117 primary adrenal insufficiency 10.3
118 steroid inherited metabolic disorder 10.2 PRL GNRH1
119 diabetes insipidus, neurohypophyseal 10.2 PRL GNRH1
120 hemosiderosis 10.2
121 cleft lip 10.2
122 growth hormone deficiency 10.2
123 rare hereditary hemochromatosis 10.2
124 pelvic varices 10.2 PRL GNRH1
125 ovarian cyst 10.2 PRL GNRH1
126 hypogonadism, male 10.2
127 46,xy sex reversal 2 10.2
128 fryns microphthalmia syndrome 10.2
129 branchiootic syndrome 1 10.2
130 adenoma 10.2
131 nr0b1-related adrenal hypoplasia congenita 10.2
132 combined pituitary hormone deficiency 10.2
133 cleft lip/palate 10.2
134 sebaceous gland disease 10.2 PRL GNRH1
135 retinitis pigmentosa 67 10.2 TACR3 TAC3
136 ovarian hyperstimulation syndrome 10.2
137 microphthalmia 10.2
138 autosomal dominant cerebellar ataxia 10.2
139 hypothyroidism 10.2
140 pituitary adenoma 10.2
141 pituitary tumors 10.2
142 uterine benign neoplasm 10.1 PRL GNRH1
143 sex development disorder 10.1 PRL KISS1 GNRH1
144 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.1
145 hypospadias 10.1
146 polycystic ovary syndrome 10.1
147 craniopharyngioma 10.1
148 diabetes insipidus 10.1
149 47,xyy 10.1
150 sox2-related eye disorders 10.1
151 cytomegalic congenital adrenal hypoplasia 10.1
152 retinitis pigmentosa 3 10.1 PRL KISS1 GNRH1
153 reproductive organ benign neoplasm 10.1 PRL GNRH1
154 neurofibromatosis, type ii 10.0
155 osteoporosis 10.0
156 mccune-albright syndrome 10.0
157 insulin-like growth factor i 10.0
158 body mass index quantitative trait locus 11 10.0
159 glycerol kinase deficiency 10.0
160 pituitary adenoma, prolactin-secreting 10.0
161 hemochromatosis, type 2a 10.0
162 bone mineral density quantitative trait locus 8 10.0
163 bone mineral density quantitative trait locus 15 10.0
164 beta-thalassemia 10.0
165 alacrima, achalasia, and mental retardation syndrome 10.0
166 split hand-foot malformation 10.0
167 hydrocephalus 10.0
168 premature ejaculation 10.0
169 gonadal dysgenesis 10.0
170 eunuchism 10.0
171 peripheral nervous system disease 10.0
172 pituitary hypoplasia 10.0
173 neuropathy 10.0
174 pnpla6-related disorders 10.0
175 47, xxy 10.0
176 48,xyyy 10.0
177 leydig cell tumor 10.0 PRL GNRH1
178 cat eye syndrome 10.0
179 hypertelorism 10.0
180 moebius syndrome 10.0
181 lipoid congenital adrenal hyperplasia 10.0
182 cystic fibrosis 10.0
183 hydrocephalus due to congenital stenosis of aqueduct of sylvius 10.0
184 megalocornea-mental retardation syndrome 10.0
185 chromosome xp21 deletion syndrome 10.0
186 yemenite deaf-blind hypopigmentation syndrome 10.0
187 body mass index quantitative trait locus 9 10.0
188 body mass index quantitative trait locus 8 10.0
189 langerhans cell histiocytosis 10.0
190 anorexia nervosa 10.0
191 body mass index quantitative trait locus 4 10.0
192 body mass index quantitative trait locus 10 10.0
193 body mass index quantitative trait locus 7 10.0
194 body mass index quantitative trait locus 12 10.0
195 body mass index quantitative trait locus 14 10.0
196 body mass index quantitative trait locus 18 10.0
197 body mass index quantitative trait locus 19 10.0
198 body mass index quantitative trait locus 20 10.0
199 hereditary ataxia 10.0
200 leukodystrophy 10.0
201 hyperandrogenism 10.0
202 hereditary hemorrhagic telangiectasia 10.0
203 telangiectasis 10.0
204 ichthyosis 10.0
205 testicular disease 10.0
206 lipid metabolism disorder 10.0
207 histiocytosis 10.0
208 cataract 10.0
209 eating disorder 10.0
210 fatty liver disease 10.0
211 alopecia 10.0
212 central congenital hypothyroidism 10.0
213 chromosomal triplication 10.0
214 head injury 10.0
215 traumatic brain injury 10.0
216 ring chromosome 10.0
217 coloboma of optic nerve 9.8 TACR3 PROKR2 GNRH1
218 anosmia, isolated congenital 9.8
219 autoimmune disease 9.8
220 gastroesophageal reflux 9.8
221 cleft palate, isolated 9.8
222 cleidocranial dysplasia 9.8
223 diabetes mellitus, noninsulin-dependent 9.8
224 duane retraction syndrome 1 9.8
225 epidermoid cysts 9.8
226 hypertriglyceridemia, familial 9.8
227 pallister-hall syndrome 9.8
228 mirror movements 1 9.8
229 neurofibromatosis, type iv, of riccardi 9.8
230 pectus excavatum 9.8
231 poland syndrome 9.8
232 dowling-degos disease 1 9.8
233 retinal detachment 9.8
234 sarcoidosis 1 9.8
235 ulnar-mammary syndrome 9.8
236 neural tube defects 9.8
237 strabismus 9.8
238 chromosome 2q35 duplication syndrome 9.8
239 varicose veins 9.8
240 vesicoureteral reflux 1 9.8
241 vitiligo-associated multiple autoimmune disease susceptibility 6 9.8
242 wolff-parkinson-white syndrome 9.8
243 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 9.8
244 adrenocortical carcinoma, hereditary 9.8
245 microphthalmia, syndromic 3 9.8
246 bardet-biedl syndrome 1 9.8
247 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.8
248 diabetes mellitus, insulin-dependent 9.8
249 achalasia-addisonianism-alacrima syndrome 9.8
250 woodhouse-sakati syndrome 9.8
251 immune deficiency disease 9.8
252 richards-rundle syndrome 9.8
253 myxedema 9.8
254 osteogenesis imperfecta, type iii 9.8
255 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 9.8
256 pseudovaginal perineoscrotal hypospadias 9.8
257 retinitis pigmentosa 9.8
258 mayer-rokitansky-kuster-hauser syndrome 9.8
259 adrenoleukodystrophy 9.8
260 ichthyosis, x-linked 9.8
261 muscular dystrophy, duchenne type 9.8
262 androgen insensitivity, partial 9.8
263 prostatic hyperplasia, benign 9.8
264 van maldergem syndrome 1 9.8
265 brittle bone disorder 9.8
266 vitiligo-associated multiple autoimmune disease susceptibility 1 9.8
267 bone mineral density quantitative trait locus 3 9.8
268 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
269 kleefstra syndrome 1 9.8
270 leukodystrophy, hypomyelinating, 5 9.8
271 diabetes mellitus, ketosis-prone 9.8
272 adrenal cortical carcinoma 9.8
273 vitelliform macular dystrophy 9.8
274 autosomal recessive disease 9.8
275 second-degree atrioventricular block 9.8
276 sleep apnea 9.8
277 autosomal recessive cerebellar ataxia 9.8
278 van maldergem syndrome 9.8
279 ectopic pregnancy 9.8
280 hypomyelinating leukodystrophy 9.8
281 oligoasthenoteratozoospermia 9.8
282 bone resorption disease 9.8
283 physical disorder 9.8
284 fibrous dysplasia 9.8
285 spina bifida occulta 9.8
286 non-alcoholic fatty liver disease 9.8
287 kleefstra syndrome 9.8
288 sensorineural hearing loss 9.8
289 neuroretinitis 9.8
290 mumps 9.8
291 rickets 9.8
292 microcephaly 9.8
293 prostatic hypertrophy 9.8
294 nephrotic syndrome 9.8
295 synostosis 9.8
296 varicocele 9.8
297 graves' disease 9.8
298 nephrocalcinosis 9.8
299 multiple epiphyseal dysplasia 9.8
300 dementia 9.8
301 gout 9.8
302 diarrhea 9.8
303 congenital toxoplasmosis 9.8
304 color blindness 9.8
305 osteopetrosis 9.8
306 polyneuropathy 9.8
307 46 xx gonadal dysgenesis 9.8
308 heart septal defect 9.8
309 epilepsy 9.8
310 atrial heart septal defect 9.8
311 dysostosis 9.8
312 dental caries 9.8
313 post-thrombotic syndrome 9.8
314 acromegaly 9.8
315 orchitis 9.8
316 glycogen storage disease 9.8
317 prostatic adenoma 9.8
318 adenocarcinoma 9.8
319 germinoma 9.8
320 temporal lobe epilepsy 9.8
321 retinitis 9.8
322 thrombophlebitis 9.8
323 adrenal carcinoma 9.8
324 adrenal cortical adenocarcinoma 9.8
325 liver disease 9.8
326 myopathy 9.8
327 non-langerhans-cell histiocytosis 9.8
328 seminoma 9.8
329 prostate disease 9.8
330 movement disease 9.8
331 chronic polyneuropathy 9.8
332 placenta disease 9.8
333 hyperthyroidism 9.8
334 crohn's disease 9.8
335 learning disability 9.8
336 waardenburg's syndrome 9.8
337 mechanical strabismus 9.8
338 meningitis 9.8
339 pathologic nystagmus 9.8
340 muscular dystrophy 9.8
341 hydrocele 9.8
342 toxoplasmosis 9.8
343 fgfr-related craniosynostosis syndromes 9.8
344 juvenile hereditary hemochromatosis 9.8
345 adrenomyeloneuropathy 9.8
346 anorchia 9.8
347 cerebellar degeneration 9.8
348 cerebellar hypoplasia 9.8
349 coloboma of iris 9.8
350 dwarfism 9.8
351 hypoadrenalism 9.8
352 kallmann syndrome 6 9.8
353 lymphocytic hypophysitis 9.8
354 ring chromosome 21 9.8
355 slipped capital femoral epiphysis 9.8
356 tuberculous meningitis 9.8
357 color vision deficiency 9.8
358 brain injury 9.8
359 chronic pain 9.8
360 headache 9.8
361 hypotonia 9.8
362 spinocerebellar degeneration 9.8
363 complex chromosomal rearrangement 9.8
364 periodic paralysis 9.8
365 premature aging 9.8
366 primary hypophysitis 9.8
367 adenomyosis 9.8 PRL GNRH1
368 hypothalamic hamartomas 9.8 KISS1R KISS1 GNRHR GNRH1
369 idiopathic central precocious puberty 9.7 TACR3 TAC3 KISS1R KISS1
370 orofacial cleft 9.4 PROKR2 GNRH1 ANOS1

Graphical network of the top 20 diseases related to Hypogonadotropism:



Diseases related to Hypogonadotropism

Symptoms & Phenotypes for Hypogonadotropism

MGI Mouse Phenotypes related to Hypogonadotropism:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.61 GNRH1 GNRHR KISS1 KISS1R PRL PROKR2
2 reproductive system MP:0005389 9.28 GNRH1 GNRHR KISS1 KISS1R PRL PROKR2

Drugs & Therapeutics for Hypogonadotropism

Drugs for Hypogonadotropism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 191, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Liraglutide Approved Phase 4 204656-20-2 44147092
2
Dihydrotachysterol Approved Phase 4 67-96-9 5281010 5311071
3
Metformin Approved Phase 4 657-24-9 14219 4091
4
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
5 Nutmeg Approved Phase 4
6
Menotropins Approved Phase 4 9002-68-0, 61489-71-2 5360545
7
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
8
Deslorelin Investigational, Vet_approved Phase 4 57773-65-6
9 Hypoglycemic Agents Phase 4
10 Incretins Phase 4
11 Luteolytic Agents Phase 4
12 Triptorelin Pamoate Phase 4
13 Fenugreek seed meal Phase 4
14 Fenugreek Phase 4
15 Tranquilizing Agents Phase 4
16 Dopamine D2 Receptor Antagonists Phase 4
17 Psychotropic Drugs Phase 4
18 Serotonin 5-HT2 Receptor Antagonists Phase 4
19 Serotonin 5-HT1 Receptor Agonists Phase 4
20 Dopamine Antagonists Phase 4
21 Serotonin Agents Phase 4
22 Antipsychotic Agents Phase 4
23 Antidepressive Agents Phase 4
24 Dopamine agonists Phase 4
25 Serotonin Receptor Agonists Phase 4
26 Serotonin Antagonists Phase 4
27 Hypolipidemic Agents Phase 4
28 Rosuvastatin Calcium Phase 4 147098-20-2
29 Anticholesteremic Agents Phase 4
30 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
31 Antimetabolites Phase 4
32 Lipid Regulating Agents Phase 4
33 Mace Phase 4
34 Pharmaceutical Solutions Phase 4
35 Follicle Stimulating Hormone Phase 4
36 Phosphodiesterase 5 Inhibitors Phase 4
37 Phosphodiesterase Inhibitors Phase 4
38 Vardenafil Dihydrochloride Phase 4
39 Vasodilator Agents Phase 4
40
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
41
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
42
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
43
Mirtazapine Approved Phase 3 85650-52-8, 61337-67-5 4205
44
Amphetamine Approved, Illicit, Investigational Phase 3 300-62-9 5826 3007
45
Histamine Approved, Investigational Phase 3 51-45-6 774
46
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
47
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
48
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
49
tannic acid Approved Phase 3 1401-55-4
50
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
51
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
52
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
53
Mecasermin Approved, Investigational Phase 3 68562-41-4
54
Desogestrel Approved Phase 3 54024-22-5 40973
55
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
56
Somatostatin Approved, Investigational Phase 3 51110-01-1, 38916-34-6 53481605
57
Zoledronic Acid Approved Phase 3 118072-93-8 68740
58
Denosumab Approved Phase 3 615258-40-7
59
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
60
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 8001-79-4
61
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
62
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
63
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
64 Analgesics, Opioid Phase 3
65 Central Nervous System Depressants Phase 3
66 Central Nervous System Stimulants Phase 3
67 Neurotransmitter Agents Phase 3
68 Dopamine Agents Phase 3
69 Dopamine Uptake Inhibitors Phase 3
70 Antiparkinson Agents Phase 3
71 Anti-Anxiety Agents Phase 3
72 Sympathomimetics Phase 3
73 Adrenergic Antagonists Phase 3
74 Adrenergic alpha-Antagonists Phase 3
75 Histamine H1 Antagonists Phase 3
76 Autonomic Agents Phase 3
77 Histamine Antagonists Phase 3
78
Histamine Phosphate Phase 3 51-74-1 65513
79 Adrenergic Agents Phase 3
80 Serotonin 5-HT3 Receptor Antagonists Phase 3
81 Interleukin 1 Receptor Antagonist Protein Phase 3
82 Antirheumatic Agents Phase 3
83 Diphosphonates Phase 3
84 Cathartics Phase 2, Phase 3
85 Castor Phase 2, Phase 3
86 Laxatives Phase 2, Phase 3
87 Gonadotropins, Pituitary Phase 3
88 Micronutrients Phase 3
89 Trace Elements Phase 3
90 Nutrients Phase 3
91 Ergocalciferols Phase 3
92 Vitamin D2 Phase 3
93 Vitamins Phase 3
94 Calciferol Phase 3
95 Contraceptives, Oral Phase 3
96 Progestins Phase 3
97 Gastrointestinal Agents Phase 3
98
Zinc Approved, Investigational Phase 1, Phase 2 7440-66-6 32051
99
Tamoxifen Approved Phase 2 10540-29-1 2733526
100
Methadone Approved Phase 1, Phase 2 76-99-3 4095
101
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 1, Phase 2 52485-79-7 40400 644073
102
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
103
Phenylephrine Approved Phase 2 59-42-7 6041
104
Oxymetazoline Approved, Investigational Phase 2 1491-59-4 4636
105
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
106
Teriparatide Approved, Investigational Phase 2 52232-67-4 16133850
107
Dihydrotestosterone Illicit, Investigational Phase 2 521-18-6 10635
108 Aromatase Inhibitors Phase 2
109 glucocorticoids Phase 2
110
Megestrol Phase 2 3562-63-8 19090 3080587
111 Appetite Stimulants Phase 2
112 Liver Extracts Phase 2
113 Prolactin Release-Inhibiting Factors Phase 2
114
Ethanol Approved Phase 1 64-17-5 702
115
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
116
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
117
Busulfan Approved, Investigational Phase 1 55-98-1 2478
118
Naloxone Approved, Vet_approved Phase 1 465-65-6 5284596
119 Ether Phase 1
120 Antilymphocyte Serum Phase 1
121 Immunosuppressive Agents Phase 1
122 Narcotic Antagonists Phase 1
123 Epoetin alfa Phase 1 113427-24-0
124
Tocopherol Approved, Investigational 1406-66-2, 54-28-4 14986
125
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
126
Cetrorelix Approved, Investigational 120287-85-6 16129715 25074887
127
Risperidone Approved, Investigational 106266-06-2 5073
128
Hydrocortisone acetate Approved, Vet_approved 50-03-3
129
Hydrocortisone Approved, Vet_approved 50-23-7 5754
130
Epinephrine Approved, Vet_approved 51-43-4 5816
131
Racepinephrine Approved 329-65-7 838
132
Parathyroid hormone Approved, Investigational 9002-64-6
133
Ganirelix Approved Early Phase 1 124904-93-4, 123246-29-7 25081094
134
Olanzapine Approved, Investigational 132539-06-1 4585
135
Haloperidol Approved 52-86-8 3559
136
Heparin Approved, Investigational 9005-49-6 772 46507594
137
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
138
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
139
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
140
Morphine Approved, Investigational 57-27-2 5288826
141
Nitric Oxide Approved 10102-43-9 145068
142
Estrone Approved 53-16-7 5870